Project 3: Investigating GALR3 as a novel target for the treatment of post-partum depression
- Lead: Blacksand Therapeutics, UK
- Funding Partners: Boehringer Ingelheim
- Project Launch: 28th June 2022
- Project Duration: 6 months
Post Partum Depression (PPD) is one of the most common, yet under-reported complications of childbirth and affects 13% of women following delivery. Galanin Receptor 3 (GalR3) is a stress and oestrogen-inducible neuropeptide, with numerous strands of evidence linking it to Post Partum Depression.
The project aims to validate GalR3 as a therapeutic treatment target for PPD, starting by investigating the effect of GalR3 antagonism on rodent neurochemistry using in vivo microdialysis techniques.
This project will provide an understanding of the role of GalR3 in PPD and whether modulating GalR3 is a viable therapeutic approach.
This project will provide an understanding of the role of GalR3 in PPD and will provide the basis for further experiments to validate GalR3 as a therapeutic treatment target.
Want to accelerate your research with the Psychiatry Consortium?
Want to be involved in funding projects like these?
The role of Medicines Discovery Catapult:
As managing partner, MDC provides critical support at every stage of the project development process. The Psychiatry Consortium Programme Manager (PM) works closely with the project partners to design a comprehensive project plan and create the contractual frameworks required to launch the project. When a project reaches the delivery phase, it’s progress and outcomes are overseen by the PM on a monthly basis.